Polyplus Secures Warburg Pincus Investment

Polyplus-transfection (Polyplus), a developer of cost-effective technology used in gene and cell therapy, has closed on a major investment from Warburg Pincus, a global private equity firm focused on growth investing. Warburg Pincus’ investment alongside the existing majority shareholder, European private equity healthcare specialist ArchiMed, will advance the development and sale of Polyplus’ breakthrough solutions for the delivery of nucleic acids (transfection) for research and the biologics-based production of therapeutic drugs and vaccines. ArchiMed and Warburg Pincus will be equal shareholders with the same voting rights. Their partnership will enable Polyplus to access the combined resources of both firms and better serve customers. Polyplus’ management team will continue to be significant minority shareholders.

Read the full article: Polyplus Secures Warburg Pincus Investment //

Source: https://www.privateequitywire.co.uk/2020/04/30/285191/polyplus-secures-warburg-pincus-investment

Scroll to Top